|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 298.16 USD | +1.68% |
|
+1.27% | -15.50% |
| 07-14 | United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says | MT |
| 06-30 | United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility (Composite) | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
| 13 | ||||||||
| 27 | ||||||||
| 23 | ||||||||
| 27 | ||||||||
| 21 | ||||||||
| 19 | ||||||||
| 18 | ||||||||
| 19 | ||||||||
| 24 | ||||||||
| 28 | ||||||||
| 23 | ||||||||
| 26 | ||||||||
| 28 | ||||||||
| 22 | ||||||||
| 22 | ||||||||
| 18 | ||||||||
| 14 | ||||||||
| - | 2 | |||||||
| 17 | ||||||||
| Average | 21 | |||||||
| Weighted average by Cap. | 23 |
- Stock Market
- Equities
- UTHR Stock
- Sector United Therapeutics Corporation
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition